The expression of TRIB3 is higher in breast cancer (Wennemers et al., 2011), ovarian cancer (Wang et al., 2020), lung cancer (Zhang X. et al., 2019), and colorectal cancer (Hua et al., 2019), and outcomes are poor. Here, TRIB3 is linked to breast cancer.